Nadia Zaffaroni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4630822/publications.pdf

Version: 2024-02-01

285 papers	21,272 citations	26630 56 h-index	11308 136 g-index
287 all docs	287 docs citations	287 times ranked	37146 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Isolation and In vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties. Cancer Research, 2005, 65, 5506-5511.	0.9	1,650
4	Human Bone Marrowâ€"Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-termIn vitroCulture and Do Not Exhibit Telomere Maintenance Mechanisms. Cancer Research, 2007, 67, 9142-9149.	0.9	649
5	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase Cĵµ. Cancer Research, 2009, 69, 2287-2295.	0.9	334
6	Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468.	16.8	311
7	Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cellular and Molecular Life Sciences, 2002, 59, 1406-1412.	5.4	246
8	Survivin as a target for new anticancer interventions. Journal of Cellular and Molecular Medicine, 2005, 9, 360-372.	3.6	227
9	Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis, 2007, 28, 1133-1139.	2.8	217
10	miR-21: an oncomir on strike in prostate cancer. Molecular Cancer, 2010, 9, 12.	19.2	189
11	Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Annals of Oncology, 2011, 22, 1682-1690.	1.2	185
12	Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resistance Updates, 2002, 5, 65-72.	14.4	177
13	TNF-Related Apoptosis-Inducing Ligand (TRAIL)â€"Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. Clinical Cancer Research, 2016, 22, 3499-3512.	7.0	158
14	Targeting survivin in cancer therapy. Expert Opinion on Therapeutic Targets, 2008, 12, 463-476.	3.4	154
15	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncology, The, 2012, 13, 810-816.	10.7	130
16	Breast cancer stem cells: An overview. European Journal of Cancer, 2006, 42, 1219-1224.	2.8	126
17	G-Quadruplex Structures in the Human Genome as Novel Therapeutic Targets. Molecules, 2013, 18, 12368-12395.	3.8	125
18	Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent. Microelectronic Engineering, 2006, 83, 1598-1601.	2.4	116

#	Article	IF	Citations
19	Photochemical Internalization: A New Tool for Drug Delivery. Current Pharmaceutical Biotechnology, 2007, 8, 362-372.	1.6	116
20	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. Cancer Research, 2006, 66, 8918-8924.	0.9	115
21	Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica, 2009, 94, 1649-1660.	3.5	111
22	Senescent stroma promotes prostate cancer progression: The role of miRâ€210. Molecular Oncology, 2014, 8, 1729-1746.	4.6	102
23	Redox-Active Polymer Microcapsules for the Delivery of a Survivin-Specific siRNA in Prostate Cancer Cells. ACS Nano, 2011, 5, 1335-1344.	14.6	99
24	Hybrid ligandâ€“alkylating agents targeting telomeric G-quadruplex structures. Organic and Biomolecular Chemistry, 2012, 10, 2798.	2.8	94
25	Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene, 2004, 23, 386-394.	5.9	92
26	Characterization of novel antisense HIF-1Î± transcripts in human cancers. Cell Cycle, 2011, 10, 3189-3197.	2.6	92
27	Novel PVA-Based Hydrogel Microparticles for Doxorubicin Delivery. Biomacromolecules, 2008, 9, 1967-1973.	5.4	91
28	Novel 1H-Pyrrolo[2,3-b]pyridine Derivative Nortopsentin Analogues: Synthesis and Antitumor Activity in Peritoneal Mesothelioma Experimental Models. Journal of Medicinal Chemistry, 2013, 56, 7060-7072.	6.4	91
29	Radiosensitization of Human Melanoma Cells by Ribozyme-Mediated Inhibition of Survivin Expression. Journal of Investigative Dermatology, 2003, 120, 648-654.	0.7	90
30	Small-Molecule Targeting of Heat Shock Protein 90 Chaperone Function:Â Rational Identification of a New Anticancer Lead. Journal of Medicinal Chemistry, 2006, 49, 7721-7730.	6.4	88
31	Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells. Current Medicinal Chemistry, 2013, 20, 1923-1945.	2.4	86
32	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochemical Pharmacology, 2014, 87, 579-597.	4.4	83
33	Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Letters, 2000, 473, 241-248.	2.8	82
34	MicroRNAs as new therapeutic targets and tools in cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 265-279.	3.4	81
35	Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. European Journal of Cancer, 2005, 41, 624-634.	2.8	80
36	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Letters, 2017, 395, 53-62.	7.2	80

#	Article	IF	Citations
37	miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death and Differentiation, 2012, 19, 1750-1760.	11.2	77
38	Targeting Loop Adenines in Gâ€Quadruplex by a Selective Oxirane. Chemistry - A European Journal, 2013, 19, 78-81.	3.3	77
39	Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochemical Pharmacology, 2013, 85, 1424-1432.	4.4	75
40	Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug. Current Medicinal Chemistry, 2013, 20, 1541-1565.	2.4	75
41	Pathophysiology and biology of peritoneal carcinomatosis. World Journal of Gastrointestinal Oncology, 2010, 2, 12.	2.0	74
42	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Molecular Cancer Therapeutics, 2005, 4, 1328-1337.	4.1	73
43	Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Molecular Cancer Therapeutics, 2006, 5, 179-186.	4.1	73
44	Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. Journal of Clinical Investigation, 2002, 109, 285-286.	8.2	73
45	Tethering Functional Ligands onto Shell of Ultrasound Active Polymeric Microbubbles. Biomacromolecules, 2006, 7, 604-611.	5.4	72
46	Inhibition of Telomerase Activity by a Hammerhead Ribozyme Targeting the RNA Component of Telomerase in Human Melanoma Cells. Journal of Investigative Dermatology, 2000, 114, 259-267.	0.7	68
47	Synthesis and Biological Evaluation (in Vitro and in Vivo) of Cyclic Arginineâ€“Glycineâ€“Aspartate (RGD) Peptidomimeticâ€“Paclitaxel Conjugates Targeting Integrin Î±_VÎ²₃. Journal of Medicinal Chemistry, 2012, 55, 10460-10474.	6.4	68
48	Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-Ã-vis Temozolomide and Antiangiogenics. Clinical Cancer Research, 2013, 19, 5192-5201.	7.0	67
49	Emerging Role of G-quadruplex DNA as Target in Anticancer Therapy. Current Pharmaceutical Design, 2017, 22, 6612-6624.	1.9	67
50	Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands. Chemistry - A European Journal, 2015, 21, 13598-13608.	3.3	65
51	A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 2009, 28, 3765-3774.	5.9	64
52	miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCÎµ and ZEB1 inhibition. Journal of Experimental and Clinical Cancer Research, 2019, 38, 51.	8.6	64
53	Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. European Journal of Cancer, 1994, 30, 1002-1007.	2.8	63
54	miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. Antioxidants and Redox Signaling, 2014, 20, 1045-1059.	5.4	63

#	Article	IF	Citations
55	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. Clinical Cancer Research, 2008, 14, 4134-4140.	7.0	61
56	XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Journal of Hematology and Oncology, 2014, 7, 46.	17.0	59
57	Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis, 2004, 25, 1129-1136.	2.8	57
58	A Computational Assay of Estrogen Receptor Î± Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers. Scientific Reports, 2018, 8, 649.	3.3	57
59	Role of FoxO Proteins in Cellular Response to Antitumor Agents. Cancers, 2019, 11, 90.	3.7	56
60	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Doseâ€“Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440.	0.8	55
61	Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget, 2015, 6, 31441-31460.	1.8	55
62	Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Research, 2003, 63, 3490-4.	0.9	55
63	Towards the definition of prostate cancer-related microRNAs: where are we now?. Trends in Molecular Medicine, 2009, 15, 381-390.	6.7	54
64	Naphthalene diimides as red fluorescent pH sensors for functional cell imaging. Organic and Biomolecular Chemistry, 2015, 13, 570-576.	2.8	54
65	Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo. PLoS ONE, 2011, 6, e29085.	2.5	54
66	Synthesis and Antitumor Activity of 3â€(2â€Phenylâ€1,3â€thiazolâ€4â€yl)â€1 Hâ€indoles and 3â€(2â€Phenylâ€1,3â€thiazolâ€4â€yl)â€1 Hâ€7â€azaindoles. ChemMedChem, 2011, 6, 1300-1309.	3.2	53
67	A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides. Journal of Medicinal Chemistry, 2014, 57, 7263-7279.	6.4	53
68	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. Autophagy, 2012, 8, 1185-1196.	9.1	51
69	Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: InÂvitro antiproliferative activity and molecular mechanism(s) of action. European Journal of Medicinal Chemistry, 2015, 94, 149-162.	5.5	51
70	Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. Journal of Clinical Investigation, 2002, 109, 285-286.	8.2	51
71	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor Î² (TGFÎ²) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Investigational New Drugs, 2014, 32, 555-560.	2.6	50
72	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. European Journal of Cancer, 2014, 50, 3021-3028.	2.8	50

#	Article	IF	Citations
73	Synthesis and Antiproliferative Activity of Substituted 3[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, Marine Alkaloid Nortopsentin Analogues. Current Medicinal Chemistry, 2014, 21, 1654-1666.	2.4	50
74	Role of proliferation in HER2 status predicted response to doxorubicin. International Journal of Cancer, 2003, 105, 568-573.	5.1	49
75	Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids and Surfaces B: Biointerfaces, 2013, 110, 434-442.	5.0	49
76	Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALTâ€associated PML bodies. International Journal of Cancer, 2008, 122, 2414-2421.	5.1	47
77	Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. British Journal of Cancer, 2009, 100, 739-746.	6.4	47
78	The 6â€year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU International, 2012, 110, 998-1003.	2.5	47
79	Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway. Current Pharmaceutical Design, 2013, 19, 883-894.	1.9	47
80	New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants. Drug Resistance Updates, 2015, 20, 1-11.	14.4	47
81	Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cellular and Molecular Life Sciences, 2003, 60, 1449-1459.	5.4	45
82	Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochemical Pharmacology, 2007, 73, 1703-1714.	4.4	45
83	Telomeres as targets for anticancer therapies. Expert Opinion on Therapeutic Targets, 2011, 15, 579-593.	3.4	45
84	On the Road to Fight Cancer: The Potential of G-Quadruplex Ligands as Novel Therapeutic Agents. International Journal of Molecular Sciences, 2021, 22, 5947.	4.1	45
85	Hyperthermia and hypoxia: new developments in anticancer chemotherapy. European Journal of Surgical Oncology, 2001, 27, 340-342.	1.0	44
86	1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. Journal of Medicinal Chemistry, 2017, 60, 3082-3093.	6.4	44
87	LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nature Communications, 2019, 10, 307.	12.8	44
88	Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. International Journal of Cancer, 1992, 52, 813-817.	5.1	43
89	Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis, 2003, 24, 851-859.	2.8	43
90	Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget, 2016, 7, 47848-47863.	1.8	43

#	Article	IF	Citations
91	A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Research, 2003, 63, 4028-36.	0.9	43
92	Synthesis, spectroscopy (IR, multinuclear NMR, ESI-MS), diffraction, density functional study and in vitro antiproliferative activity of pyrazole-beta-diketone dihalotin(IV) compounds on 5 melanoma cell lines. Journal of Inorganic Biochemistry, 2006, 100, 58-69.	3.5	42
93	Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents. European Journal of Medicinal Chemistry, 2013, 63, 387-400.	5.5	42
94	microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies. Seminars in Cancer Biology, 2017, 44, 132-140.	9.6	42
95	Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance. Current Medicinal Chemistry, 2017, 24, 2860-2886.	2.4	42
96	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine, 2019, 39, 215-225.	6.1	41
97	Induction of Endoplasmic Reticulum Stress Response by the Indole-3-Carbinol Cyclic Tetrameric Derivative CTet in Human Breast Cancer Cell Lines. PLoS ONE, 2012, 7, e43249.	2.5	41
98	Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines. Biochemical Pharmacology, 2007, 73, 773-781.	4.4	40
99	miRNAs in tumor radiation response: bystanders or participants?. Trends in Molecular Medicine, 2014, 20, 529-539.	6.7	40
100	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood, 2015, 125, 1768-1771.	1.4	40
101	Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma. Journal of Medicinal Chemistry, 2016, 59, 7223-7238.	6.4	40
102	Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. Journal of Hematology and Oncology, 2017, 10, 19.	17.0	40
103	Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells. European Journal of Cancer, 2002, 38, 1792-1801.	2.8	39
104	Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget, 2015, 6, 13119-13132.	1.8	39
105	Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. European Journal of Cancer, 2001, 37, 1953-1962.	2.8	38
106	Dimerizable Redox-Sensitive Triazine-Based Cationic Lipids for inâ€…vitro Gene Delivery. ChemMedChem, 2007, 2, 292-296.	3.2	38
107	Redox-Sensitive PEGâ€“Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells. Biomacromolecules, 2015, 16, 2168-2178.	5.4	38
108	Possible Regulation of Telomerase Activity by Transcription and Alternative Splicing of Telomerase Reverse Transcriptase in Human Melanoma. Journal of Investigative Dermatology, 2001, 116, 867-873.	0.7	37

#	Article	IF	Citations
109	Targeting the telosome: Therapeutic implications. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 309-316.	3.8	37
110	TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy Effects. Cancer Research, 2011, 71, 6382-6390.	0.9	37
111	Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. OncoImmunology, 2015, 4, e1040214.	4.6	37
112	The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. Breast Cancer Research, 2011, 13, R33.	5.0	36
113	Targeting DNA Topoisomerase I with Non-Camptothecin Poisons. Current Medicinal Chemistry, 2012, 19, 1238-1257.	2.4	36
114	Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochemical Pharmacology, 2012, 83, 27-36.	4.4	36
115	Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma. Analytical Cellular Pathology, 2007, 29, 453-466.	1.4	35
116	Lack of a correlation between micronucleus formation and radiosensitivity in established and primary cultures of human tumours. British Journal of Cancer, 1994, 70, 1112-1117.	6.4	34
117	Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy. Current Medicinal Chemistry, 2011, 18, 4237-4249.	2.4	34
118	FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models. Biochemical Pharmacology, 2018, 147, 93-103.	4.4	34
119	DNA Double-strand Break Repair and Radiation Response in Human Tumour Primary Cultures. International Journal of Radiation Biology, 1994, 66, 279-285.	1.8	33
120	Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres. Clinical Cancer Research, 2005, 11, 2832-2839.	7.0	33
121	PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicology and Applied Pharmacology, 2016, 310, 9-19.	2.8	33
122	Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads. Chemistry - A European Journal, 2017, 23, 5188-5192.	3.3	33
123	Rational design of allosteric modulators of the aromatase enzyme: AnÂunprecedented therapeutic strategy to fight breast cancer. European Journal of Medicinal Chemistry, 2019, 168, 253-262.	5.5	33
124	Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. Journal of Pathology, 2002, 198, 37-46.	4.5	32
125	Characterization of stress response in human retinal epithelial cells. Journal of Cellular and Molecular Medicine, 2013, 17, 103-115.	3.6	32
126	Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4594-4602.	3.6	31

#	Article	IF	Citations
127	Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells. Current Medicinal Chemistry, 2016, 23, 1496-1512.	2.4	31
128	Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies. Current Pharmaceutical Design, 2005, 11, 1105-1117.	1.9	30
129	Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer, 2010, 10, 254.	2.6	30
130	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. European Journal of Cancer, 2010, 46, 2837-2848.	2.8	30
131	Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. OncoImmunology, 2016, 5, e1234571.	4.6	30
132	Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. Journal of Pathology, 2003, 201, 127-133.	4.5	29
133	Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cellular and Molecular Life Sciences, 2004, 61, 1764-74.	5.4	29
134	Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D. Bioorganic and Medicinal Chemistry, 2011, 19, 4971-4984.	3.0	29
135	Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy, 2012, 14, 80-90.	0.7	29
136	The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochemical Pharmacology, 2012, 84, 163-171.	4.4	29
137	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. Oncotarget, 2014, 5, 4516-4528.	1.8	29
138	YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. International Journal of Cancer, 2015, 136, 299-309.	5.1	29
139	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. British Journal of Cancer, 2020, 123, 644-656.	6.4	29
140	The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications. Cancers, 2020, 12, 949.	3.7	29
141	Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Current Pharmaceutical Design, 2013, 19, 883-94.	1.9	29
142	Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. European Journal of Cancer, 2000, 36, 2137-2145.	2.8	28
143	TCEAL7 Inhibition of c-Myc Activity in Alternative Lengthening of Telomeres Regulates hTERT Expression. Neoplasia, 2010, 12, 405-IN6.	5.3	28
144	Assessment of gene promoter G-quadruplex binding and modulation by a naphthalene diimide derivative in tumor cells. International Journal of Oncology, 2015, 46, 369-380.	3.3	28

#	Article	IF	Citations
145	Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide. Journal of Medicinal Chemistry, 2018, 61, 8625-8638.	6.4	28
146	Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions. British Journal of Cancer, 2001, 84, 1387-1390.	6.4	27
147	Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. European Journal of Cancer, 2001, 37, 649-659.	2.8	27
148	Biomolecular markers of outcome prediction in prostate cancer. Cancer, 2009, 115, 3058-3067.	4.1	27
149	Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 2010, 11, 532.	2.8	27
150	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. Clinical Cancer Research, 2012, 18, 3316-3327.	7.0	27
151	Improved Apoptotic Cell Death in Drug-Resistant Nonâ€“Small-Cell Lung Cancer Cells by Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Based Treatment. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 360-371.	2.5	26
152	Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. Cancer Letters, 2014, 347, 212-224.	7.2	26
153	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European Journal of Cancer, 2017, 76, 84-92.	2.8	26
154	Telomerase Activity in Benign and Malignant Breast Lesions: a Pilot Prospective Study on Fine-Needle Aspirates. Journal of the National Cancer Institute, 1998, 90, 537-539.	6.3	25
155	High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. British Journal of Cancer, 2008, 98, 1467-1474.	6.4	25
156	The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas. Cancer Letters, 2016, 382, 245-254.	7.2	25
157	Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discovery Medicine, 2010, 9, 212-8.	0.5	25
158	Reliability of anin vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer, 1985, 56, 450-456.	4.1	24
159	Ribozyme-mediated inhibition of PKC? sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate, 2003, 54, 133-143.	2.3	24
160	Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Proliferation, 2007, 40, 905-920.	5.3	24
161	Multiple effects of the Na+/H+ antiporter inhibitor HMA on cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1586-1598.	4.9	24
162	Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. Cancer Letters, 2018, 415, 187-197.	7.2	24

#	Article	IF	Citations
163	Î´â€Tocotrienol sensitizes and reâ€sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPKâ€mediated apoptosis. Cell Proliferation, 2021, 54, e13111.	5.3	24
164	Nanoparticles for Ferroptosis Therapy in Cancer. Pharmaceutics, 2021, 13, 1785.	4.5	24
165	Synergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 498-509.	3.6	23
166	[1,2]Oxazolo[5,4- e]isoindoles as promising tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 840-851.	5.5	23
167	miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an â€œALT-likeâ€phenotype in diffuse malignant peritoneal mesothelioma cells. Journal of Hematology and Oncology, 2017, 10, 140.	17.0	23
168	Effect of hyperthermia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma. International Journal of Hyperthermia, 1992, 8, 341-349.	2.5	22
169	Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGDâ€“paclitaxel conjugates for integrin-assisted drug delivery. Organic and Biomolecular Chemistry, 2015, 13, 7530-7541.	2.8	22
170	Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor. Biochemical Pharmacology, 2015, 94, 79-90.	4.4	22
171	Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches. Cellular and Molecular Life Sciences, 2016, 73, 2531-2542.	5.4	22
172	Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer. Oncotarget, 2016, 7, 49649-49663.	1.8	22
173	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World Journal of Gastrointestinal Oncology, 2010, 2, 76.	2.0	22
174	Application of anin vitro antimetabolic assay to human germ cell testicular tumors for the preclinical evaluation of drug sensitivity. Cancer, 1986, 58, 1441-1447.	4.1	21
175	Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes. Anti-Cancer Agents in Medicinal Chemistry, 2002, 2, 605-612.	7.0	21
176	Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro-Oncology, 2012, 14, 736-744.	1.2	21
177	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. Cancers, 2019, 11, 1015.	3.7	21
178	Resveratrol and Prostate Cancer: The Power of Phytochemicals. Current Medicinal Chemistry, 2021, 28, 4845-4862.	2.4	21
179	Antiâ€tumor activity of CpGâ€ODN aerosol in mouse lung metastases. International Journal of Cancer, 2013, 133, 383-393.	5.1	20
180	Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements. Biophysical Journal, 2016, 110, 2151-2161.	0.5	20

#	Article	IF	Citations
181	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. Tumori, 2017, 103, 464-474.	1.1	20
182	miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells. Oncotarget, 2016, 7, 18594-18604.	1.8	20
183	Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells, 1995, 13, 77-85.	3.2	19
184	Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. British Journal of Cancer, 1999, 81, 252-260.	6.4	19
185	Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer. Frontiers in Chemistry, 2019, 7, 369.	3.6	19
186	High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors. Journal of Translational Medicine, 2013, 11, 25.	4.4	18
187	Pleiotropic antitumor effects of the panâ€HDAC inhibitor ITF2357 against câ€Mycâ€overexpressing human Bâ€cell nonâ€Hodgkin lymphomas. International Journal of Cancer, 2014, 135, 2034-2045.	5.1	18
188	Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 732-739.	2.8	18
189	Necroptosis and Prostate Cancer: Molecular Mechanisms and Therapeutic Potential. Cells, 2022, 11, 1221.	4.1	18
190	Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. International Journal of Cell Cloning, 1989, 7, 385-394.	1.6	17
191	Validation of Telomerase and Survivin as Anticancer Therapeutic Targets Using Ribozymes and Small-Interfering RNAs. , 2007, 361, 239-264.		17
192	Remarkable interference with telomeric function by a G-quadruplex selective bisantrene regioisomer. Biochemical Pharmacology, 2010, 79, 1781-1790.	4.4	17
193	Antitumor Activity of a Novel Homodimeric SMAC Mimetic in Ovarian Carcinoma. Molecular Pharmaceutics, 2014, 11, 283-293.	4.6	17
194	CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. Journal of Translational Medicine, 2016, 14, 25.	4.4	17
195	Plantâ€Derived Stilbenoids as DNAâ€Binding Agents: From Monomers to Dimers. Chemistry - A European Journal, 2021, 27, 8832-8845.	3.3	17
196	PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins. Oncotarget, 2015, 6, 8736-8749.	1.8	17
197	Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IVnon-small-cell lung cancer. Annals of Oncology, 2003, 14, 242-247.	1.2	16
198	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. British Journal of Cancer, 2014, 110, 26-33.	6.4	16

#	Article	IF	Citations
199	Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells. Biochemical Pharmacology, 2017, 136, 40-50.	4.4	16
200	Distinct biological responses of metastatic castration resistant prostate cancer cells upon exposure to G-quadruplex interacting naphthalenediimide derivatives. European Journal of Medicinal Chemistry, 2019, 177, 401-413.	5.5	16
201	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. Oncotarget, 2016, 7, 75503-75517.	1.8	16
202	Drug Combinations with Proteasome Inhibitors in Antitumor Therapy. Current Pharmaceutical Design, 2013, 19, 4094-4114.	1.9	16
203	Effect of ionizing radiation on cell-cycle progression and cyclin B1 expression in human melanoma cells. , 1996, 66, 104-109.		15
204	Telomere maintenance in wilms tumors: First evidence for the presence of alternative lengthening of telomeres mechanism. Genes Chromosomes and Cancer, 2011, 50, 823-829.	2.8	15
205	Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological Oncology, 2018, 36, 360-362.	1.7	15
206	[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. PLoS ONE, 2018, 13, e0197754.	2.5	15
207	Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. Oncotarget, 2016, 7, 58903-58914.	1.8	15
208	MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets. Current Medicinal Chemistry, 2013, 20, 1566-1584.	2.4	15
209	In vitro cytotoxic activity of taxol' and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells, 1993, 11, 528-535.	3.2	14
210	Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. , 1998, 78, 377-384.		14
211	Design of Disruptors of the Hsp90â€“Cdc37 Interface. Molecules, 2020, 25, 360.	3.8	14
212	MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising. Current Pharmaceutical Design, 2014, 20, 6404-6421.	1.9	14
213	In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. European Journal of Cancer, 1994, 30, 1534-1540.	2.8	13
214	Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs. Anti-Cancer Drugs, 1997, 8, 509-516.	1.4	13
215	ALTâ€associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. Journal of Pathology, 2008, 214, 410-414.	4.5	13
216	Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells. Biochemical Pharmacology, 2011, 82, 778-788.	4.4	13

#	Article	IF	Citations
217	Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy. Disease Markers, 2018, 2018, 1-9.	1.3	13
218	RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy. Current Topics in Medicinal Chemistry, 2012, 12, 69-78.	2.1	12
219	The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands. Cells, 2019, 8, 1274.	4.1	12
220	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers, 2021, 13, 2380.	3.7	12
221	RNA Interference-Mediated Validation of Genes Involved in Telomere Maintenance and Evasion of Apoptosis as Cancer Therapeutic Targets. Methods in Molecular Biology, 2009, 487, 1-28.	0.9	12
222	Transforming the Chemical Structure and Bioâ€Nano Activity of Doxorubicin by Ultrasound for Selective Killing of Cancer Cells. Advanced Materials, 2022, 34, e2107964.	21.0	12
223	Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. European Journal of Cancer, 1996, 32, 1766-1773.	2.8	11
224	Targeting MicroRNAs to Withstand Cancer Metastasis. Methods in Molecular Biology, 2015, 1218, 415-437.	0.9	11
225	Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 610.	3.7	11
226	miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression. Cells, 2020, 9, 435.	4.1	11
227	Structural Requirements of Benzofuran Derivatives Dehydro-Î´- and Dehydro-Îµ-Viniferin for Antimicrobial Activity Against the Foodborne Pathogen Listeria monocytogenes. International Journal of Molecular Sciences, 2020, 21, 2168.	4.1	11
228	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin downâ€regulation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 83.	8.6	11
229	Balanced dual acting compounds targeting aromatase and estrogen receptor Î± as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer. European Journal of Medicinal Chemistry, 2021, 224, 113733.	5.5	11
230	Heterogeneous Radiation and Heat Sensitivityin Vitroof Human Melanoma Xenograft Lines Established from Different Lesions in the Same Patient. International Journal of Radiation Biology, 1990, 57, 1113-1122.	1.8	10
231	Ligands Tethering to Biocompatible Ultrasound Active Polymeric Microbubbles Surface. Macromolecular Symposia, 2006, 234, 94-101.	0.7	10
232	Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma. Cancers, 2019, 11, 408.	3.7	10
233	Ferroptosis Inducers for Prostate Cancer Therapy. Current Medicinal Chemistry, 2022, 29, 4185-4201.	2.4	10
234	Modulation by Ionidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. Breast Cancer Research and Treatment, 1997, 42, 103-112.	2.5	9

#	Article	IF	Citations
235	Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies. Cancers, 2011, 3, 1405-1425.	3.7	9
236	Unravelling â€œoff-targetâ€•effects of redox-active polymers and polymer multilayered capsules in prostate cancer cells. Nanoscale, 2015, 7, 6261-6270.	5.6	9
237	Synthetic sulfoglycolipids targeting the serineâ€“threonine protein kinase Akt. Bioorganic and Medicinal Chemistry, 2016, 24, 3396-3405.	3.0	9
238	Synthesis and Superpotent Anticancer Activity of Tubulysins Carrying Nonâ€hydrolysable Nâ€Substituents on Tubuvaline. Chemistry - A European Journal, 2017, 23, 5842-5850.	3.3	9
239	New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. Anticancer Research, 2020, 40, 4913-4919.	1.1	9
240	Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 381.	8.6	9
241	Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia, 2010, 24, 1368-1370.	7.2	8
242	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 8.e1-8.e8.	1.6	8
243	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. Cells, 2020, 9, 2231.	4.1	8
244	SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. Cancers, 2020, 12, 1462.	3.7	8
245	Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers, 2021, 13, 2433.	3.7	8
246	miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. Pharmaceuticals, 2021, 14, 523.	3.8	8
247	Synthesis and in Vitro Anti-Proliferative Activity of Racemic Trifluoro-Casodex® (Bicalutamide). Letters in Organic Chemistry, 2005, 2, 447-449.	0.5	7
248	Ligand selection from the analysis of protein conformational substates: new leads targeting the N-terminal domain of Hsp90. RSC Advances, 2012, 2, 4268.	3.6	7
249	Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Journal of Inorganic Biochemistry, 2012, 113, 94-101.	3.5	7
250	Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number. Clinical Cancer Research, 2014, 20, 995-1006.	7.0	7
251	Novel 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent: a patent evaluation of WO2015048365 (A1). Expert Opinion on Therapeutic Patents, 2016, 26, 637-642.	5.0	7
252	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. Frontiers in Immunology, 2019, 10, 2514.	4.8	7

#	Article	IF	Citations
253	Luminescent dinuclear rhenium(I) PNA conjugates for microRNA-21 targeting: Synthesis, chemico-physical and biological characterization. Journal of Organometallic Chemistry, 2019, 887, 32-39.	1.8	7
254	Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. European Urology Oncology, 2019, 2, 277-285.	5.4	7
255	MIR205HG/LEADR Long Noncoding RNA Binds to Primed Proximal Regulatory Regions in Prostate Basal Cells Through a Triplex- and Alu-Mediated Mechanism. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	6
256	Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay. Investigational New Drugs, 1987, 5, 245-50.	2.6	5
257	Flunarizine as a modulator of doxorubicin resistance in human colon-adenocarcinoma cells. International Journal of Cancer, 1993, 55, 636-639.	5.1	5
258	Modulation of melphalan cytotoxic activity in human melanoma cell lines. Anti-Cancer Drugs, 1996, 7, 604-612.	1.4	5
259	Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. International Journal of Oncology, 2010, 37, 133-42.	3.3	5
260	MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs. Current Drug Targets, 2016, 17, 257-265.	2.1	5
261	Comparison of an antimetabolic assay and an antiproliferative assay, both using 3h-thymidine incorporation, to test drug sensitivity of human tumors. International Journal of Cell Cloning, 1988, 6, 392-403.	1.6	4
262	Coexpression of survivin and TERT in soft-tissue sarcoma. Lancet, The, 2002, 360, 877.	13.7	4
263	Drug Sensitivity of Different Tumor Lesions from the Same Patient Evaluated by a Short-Term Assay. Tumori, 1988, 74, 137-144.	1.1	3
264	Activity of a chartreusin analog, elsamicin A, on breast cancer cells. Anti-Cancer Drugs, 1992, 3, 677-682.	1.4	3
265	Effects of liposome-entrapped annamycin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis. Journal of Cellular Biochemistry, 2001, 81, 9-22.	2.6	3
266	Strategies to Translate Preclinical Information to Breast Cancer Patient Benefit. Journal of the National Cancer Institute Monographs, 2011, 2011, 55-59.	2.1	3
267	miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. Cancer Gene Therapy, 2022, 29, 1394-1404.	4.6	3
268	In vitro activity of 4? -iodo-4? -deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay. Investigational New Drugs, 1990, 8, 143-4.	2.6	2
269	Therapeutic Uses of Peptide Nucleic Acids (PNA) in Oncology. , 2006, , 171-180.		2
270	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. , 2020, , 117-129.		2

#	Article	IF	Citations
271	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. Cancers, 2021, 13, 5850.	3.7	2
272	Therapeutic uses of peptide nucleic acids (PNA) in oncology. International Journal of Peptide Research and Therapeutics, 2003, 10, 287-296.	1.9	1
273	Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. International Journal of Oncology, 2007, , .	3.3	1
274	Targeting Survivin in Cancer Therapy: Pre-clinical Studies. , 2010, , 147-168.		1
275	EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group. European Journal of Cancer, Supplement, 2012, 10, 128-140.	2.2	1
276	Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. Cancers, 2022, 14, 2624.	3.7	1
277	Comparison between an antimetabolic assay and a cytocidal assay for in vitro chemosensitivity testing of human tumors. Cytotechnology, 1987, 1, 77-78.	1.6	0
278	Therapeutic uses of peptide nucleic acids (PNA) in oncology. International Journal of Peptide Research and Therapeutics, 2003, 10, 287-296.	0.1	0
279	Use of ribozymes in validation of targets involved in tumor progression. Drug Discovery Today: Technologies, 2004, 1, 119-124.	4.0	0
280	Therapeutic uses of peptide nucleic acids (PNA) in oncology. International Journal of Peptide Research and Therapeutics, 2005, 10, 287-296.	1.9	0
281	Response to â€˜Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanismsâ€™. Oncogene, 2012, 31, 267-268.	5.9	0
282	New Directions for Biologic Targets in Urothelial Carcinoma â€“ Letter. Molecular Cancer Therapeutics, 2012, 11, 2306-2306.	4.1	0
283	Preface: Special Issue on MicroRNAs as Novel Cancer Biomarkers and Therapeutic Targets. Critical Reviews in Oncogenesis, 2013, 18, v-vi.	0.4	0
284	Peritoneal Mesothelioma. Updates in Surgery Series, 2015, , 243-254.	0.1	0
285	MicroRNAs in Prostate Cancer: A Possible Role as Novel Biomarkers and Therapeutic Targets?. , 2011, , 145-162.		0